NCT05103605Active, not recruiting
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
Source: ClinicalTrials.gov · Last updated 1 Dec 2025
Brief summary (registry, in English)
This is an observational multicenter study. A cross-sectional descriptive study of patients with locally advanced or metastatic Non Small Cell Lung Cancer with activating EGFR mutation treated by any first line therapy will be used to identify cohort with a prospective follow-up of patients initiating a treatment by osimertinib in first line * A cross-sectional descriptive study of all patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated by any first line therapy will be collected at the study participating sites. The study which is transversal will allow to characterize the population of patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated in first line, the day of first line initiation. * Additionally, a prospective study targeting a cohort of patients focusing on patients with locally advanced or metastatic NSCLC with activating EGFR mutation initiating a treatment by osimertinib in first line will be conducted to address describe in real life conditions the 36-months overall survival, patients baseline characteristics, disease evolution, sequencing and treatment patterns, and quality of life
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 274 (actual)
- First submitted
- 21 Oct 2021
- Start date
- 12 May 2021
- Primary completion date
- 15 Jan 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT05103605
What you commit to
- Study type: Observational
- Participants enrolled: 274
- From 12 May 2021 to the primary completion date, 15 Jan 2026
- 46 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients enrolled in interventional clinical trials (first line treatment for a NSCLC) during the study period.
Who the study is looking for
- Descriptive cross-sectional survey (Population B)
- Adult patients (≥ 18 years old),
- Patients newly treated in first line (1L) for locally advanced or metastatic NSCLC,
- Patients with activating EGFR mutation-positive,
- Patient informed and not opposed to these data collection.
- Prospective cohort (Population A)
- Patient meeting part B inclusion criteria,
- Patients newly treated in 1L by osimertinib,
- Patient with common EGFR mutation-positive (exon 19 deletion or L858R mutation, alone or co-occuring with other EGFR mutations).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (46)
Sites in registry order. Save your city in your profile to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.